{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:26:40Z","timestamp":1791433600229,"version":"4.3.3"},"reference-count":11,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2024,1]]},"abstract":"\n Introduction<\/jats:title>\n Etoposide is a key component of many pediatric chemotherapy regimens for both hematologic and solid tumors. It is well documented that patients receiving etoposide may experience infusion-related reactions.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n In this study, total doses of etoposide and etoposide phosphate were identified, and infusion-related reactions were retrospectively evaluated at a large pediatric oncology ambulatory clinic. The primary outcome was to determine the rate of acute infusion-related reactions to etoposide. A secondary objective was to identify potential risk factors associated with such reactions.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Overall, 1463 doses of etoposide were dispensed to 150 unique patients and 15 patients (10%) experienced etoposide infusion-related reactions. Of the 15 patients that experienced etoposide infusion-related reaction, two were successfully able to tolerate subsequent infusions with a slower etoposide infusion rate and pre-medications. The remaining patients changed drug formulation to etoposide phosphate ( n\u2009=\u200912) or continued therapy without any formulation of etoposide ( n\u2009=\u20091). Patients with classical Hodgkin's lymphoma experienced a higher incidence of infusion-related reactions compared to the overall patient population (30.5% vs. 10%) and made up 73.3% of all infusion-related reactions during the study period.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n During the examined study period, 10% of patients experienced an acute infusion-related reaction to etoposide. This review builds on previous literature concluding that additional monitoring may be warranted in patients with classical Hodgkin's lymphoma receiving etoposide.<\/jats:p>\n <\/jats:sec>","DOI":"10.1177\/10781552231215087","type":"journal-article","created":{"date-parts":[[2023,11,14]],"date-time":"2023-11-14T01:50:46Z","timestamp":1699926646000},"page":"197-200","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Acute infusion-related reactions in pediatric patients receiving etoposide at a tertiary cancer center"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-0261-7979","authenticated-orcid":false,"given":"Patrick","family":"McBride","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Degar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"key":"bibr1-10781552231215087","volume-title":"Etoposide (package insert)","author":"Pfizer Inc","year":"2022"},{"key":"bibr2-10781552231215087","doi-asserted-by":"publisher","DOI":"10.1002\/phar.2603"},{"key":"bibr3-10781552231215087","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.01.010"},{"key":"bibr4-10781552231215087","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600003"},{"key":"bibr5-10781552231215087","doi-asserted-by":"publisher","DOI":"10.1592\/phco.19.11.989.31566"},{"key":"bibr6-10781552231215087","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910215)67:4<1070::AID-CNCR2820670434>3.0.CO;2-X"},{"key":"bibr7-10781552231215087","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.6.1080"},{"key":"bibr8-10781552231215087","doi-asserted-by":"publisher","DOI":"10.3399\/BJGP.2021.0617"},{"key":"bibr9-10781552231215087","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219858390"},{"key":"bibr10-10781552231215087","volume-title":"Etoposide (package insert)","author":"Hikma Inc","year":"2019"},{"key":"bibr11-10781552231215087","volume-title":"Etoposide (package insert)","author":"Accord Healthcare Inc","year":"2020"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231215087","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10781552231215087","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10781552231215087","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:29:15Z","timestamp":1777688955000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10781552231215087"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1177\/10781552231215087"],"URL":"https:\/\/doi.org\/10.1177\/10781552231215087","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]}}}